News for Rhythm Pharmaceuticals, Inc. (RYTM.MX)

Summary Rhythm Pharmaceuticals Inc (RYTM), a Boston-based biopharmaceutical company specializing in rare neuroendocrine diseases, announced on July 22, 2025, th

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM), a global commercial-stage biopharmaceutical company focused on transforming th

Rhythm Pharmaceuticals (RYTM) receives a positive outlook as Canaccord Genuity maintains its "Buy" rating on the stock. This affirmation of confidence comes alo

Significant clinical data presented by Rhythm Pharmaceuticals (RYTM) on MC4R agonists for acquired hypothalamic obesity. Phase 3 TRANSCEND trial for set

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity -

Rhythm Pharmaceuticals (RYTM) is drawing attention as biotech analysts focus on the potential of its treatment, Setmelanotide, for addressing acquired hypothala

Rhythm Pharmaceuticals (RYTM) has increased its common stock offering to $175 million, up from the previous plan of $150 million. The pricing for this offering

BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM) (”œRhythm”), a global, commercial-stage biopharmaceutical company dedicated

Summary: Rhythm Pharmaceuticals (RYTM) initiated an upsized public offering, impacting its stock by a 3.3% premarket decline. Wall Street analysts projec

Rhythm Pharmaceuticals (RYTM) has revealed the pricing details for its expanded public offering, involving 2,058,824 shares of its common stock, each priced at

Rhythm Pharmaceuticals (RYTM) launches an upsized public offering of 2,058,824 shares at $85 per share. The company expects to raise approximately $175

BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) ('Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced the pricing of its upsized public offering of 2,058,824 shares of its common stock at a public offering price of $85.00 per share. In addition, Rhythm also granted the underwriters a 30-day option to purchase up to an additional 308,823 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Rhythm, and excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are being offered by Rhythm. The offering is expected to close on or about July 11, 2025, subject to the satisfaction of customary closing conditions.

Goldman Sachs has reinstated its coverage of Rhythm Pharmaceuticals (RYTM) with an optimistic outlook, assigning a Buy rating and a price target of $97. The inv

Summary On July 9, 2025, Rhythm Pharmaceuticals Inc (RYTM), a global biopharmaceutical company focused on rare neuroendocrine diseases, announced a proposed pub

Rhythm Pharmaceuticals, trading under the ticker RYTM, has revealed its intention to conduct a public offering worth $150 million in common stock. The entire of

Rhythm Pharmaceuticals (RYTM) announces a $150 million public offering of common stock with a 30-day option for underwriters to purchase an additional $22.

U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session af...

Rhythm Pharmaceuticals, Inc. may be ripe in a year. At that time, setmelanotide should be approved for HO in the U.S. and Europe. Click for my RYTM stock update.

Rhythm Pharmaceuticals (RYTM) received a reaffirmation of confidence from JMP Securities, as analyst Jonathan Wolleben maintained his "Market Outperform" rating